A Phase 2 interventional study of Empagliflozin and BI 10773 in Diabetes Mellitus, Type 2 and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-11.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 97th largest by enrollment, is one of 4 that started in 2013, is one of 17 in phase 2, and was the 28th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 88th largest by enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2013, is one of 18 in phase 2, and was the 71st registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
healthy controls
Drug: BI 10773
patients with type 2 diabetes mellitus
Drug: Empagliflozin
open label
Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)
Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Day 14). Per-protocol set (PPS): PPS consisted of all subjects and patients in the TS who completed the treatment day 14 clamping study without any relevant deviations either in their treatment regimen or in the performance and timing of the measurements.
Time frame: Baseline and Day 14
39 subjects were enrolled in the trial; 37 subjects were treated with the trial treatment, 2 subjects were not treated with the trial treatment (1 subject from type 2 diabetes mellitus (T2DM) patients arm and 1 subject from the Healthy subjects arm were not treated)
| Milestone | T2DM Patients | Healthy Subjects |
|---|---|---|
| Started | 18 | 19 |
| Completed | 15 | 16 |
| Not completed | 3 | 3 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Other adverse event | 1 | 3 |
Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Day 14). Per-protocol set (PPS): PPS consisted of all subjects and patients in the TS who completed the treatment day 14 clamping study without any relevant deviations either in their treatment regimen or in the performance and timing of the measurements.
| (milligram / minute/ 1.73 square meters) | T2DM Patients | Healthy Subjects |
|---|---|---|
| Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14) | -321.7 ± 214.9 | -256.9 ± 100.0 |
Collected over From first drug administration through the residual effect and/or follow-up period, up to 21 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T2DM Patients | — | 0/18 (0%) | 14/18 (77.8%) |
| Healthy Subjects | — | 0/19 (0%) | 16/19 (84.2%) |
| Event | T2DM Patients | Healthy Subjects |
|---|---|---|
| PollakiuriaRenal and urinary disorders | 9/18 | 6/19 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/18 | 7/19 |
| Dry mouthGastrointestinal disorders | 4/18 | 0/19 |
| ErythemaSkin and subcutaneous tissue disorders | 2/18 | 4/19 |
| VomitingGastrointestinal disorders | 0/18 | 3/19 |
| HeadacheNervous system disorders | 0/18 | 2/19 |
| PhlebitisVascular disorders | 0/18 | 2/19 |
| NauseaGastrointestinal disorders | 1/18 | 2/19 |
| PainGeneral disorders | 1/18 | 2/19 |
| SwellingGeneral disorders | 1/18 | 2/19 |
The treated set (TS) consisted of all subjects and patients who were treated with at least one dose of empagliflozin.
| Age, Continuous(years) | T2DM Patients | Healthy Subjects | Total |
|---|---|---|---|
| Mean | 55.1 ± 5.5 | 56.7 ± 6.3 | 55.9 ± 5.9 |
| Sex: Female, Male(Participants) | T2DM Patients | Healthy Subjects | Total |
|---|---|---|---|
| Female | 5 | 7 | 12 |
| Male | 13 | 12 | 25 |
The record gives a start of Jun 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 7 months after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin